SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small ...

In a regulatory filing, SpringWorks Therapeutics (SWTX) disclosed that its CEO Saqim Islam sold 48K shares of common stock on February 10th in ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

This article summarizes the most significant insider buying and selling activities reported for Wednesday, February 12, 2025, ...

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Willis Towers Watson Public Limited (NASDAQ:WTW). In a filing disclosed on February 11th, the Representative disclosed ...

2-Year U.S. Treasury Note Continuous Contract $102.734 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $106.461 0.000 0.00% 10-Year U.S. Treasury Note Continuous Contract $109.188-0.047 ...